Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses
Completed
- Conditions
- COVID-19
- Registration Number
- NCT04380779
- Lead Sponsor
- Manuel Monreal
- Brief Summary
The main objectives are:
* To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses.
* To identify variables associated to higher risk of bleeding.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2430
Inclusion Criteria
- Patients infected with COVID-19 treated with higher than recommended thromboprophylaxis doses.
- Admission to hospital.
Exclusion Criteria
- Patients treated with ECMO (Extracorporeal membrane oxygenation).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bleeding events and complications 30 days Study endpoints are clinically recognized (and objectively confirmed) major and minor bleeding complications, and death.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link elevated thromboprophylaxis doses to increased bleeding risk in severe COVID-19?
How does high-dose thromboprophylaxis compare to standard anticoagulation protocols in hospitalized COVID-19 patients?
Are there specific biomarkers that identify patients most at risk for major bleeding with escalated thromboprophylaxis in acute respiratory distress syndrome (ARDS) from SARS-CoV-2 infection?
What are the optimal management strategies for hemorrhagic complications in patients receiving therapeutic anticoagulation for hypercoagulable states associated with coronavirus disease 2019?
How do combination approaches of thromboprophylaxis with antiplatelet agents compare to monotherapy in preventing thromboembolic events while minimizing bleeding in critically ill SARS-CoV-2 patients?
Trial Locations
- Locations (1)
Manuel Monreal
🇪🇸Badalona, Barcelona, Spain
Manuel Monreal🇪🇸Badalona, Barcelona, Spain